Expression of the SART1 tumor rejection antigen in renal cell carcinoma

Urological Research

Volumn 28, Issue 3, 2000, Pages 178-184

  Shintaku, I ^a   Kawagoe, N ^b   Yutani, S ^b   Hoshi, S ^a   Orikasa, S ^a   Yoshizumi, O ^c   Itoh, K ^b  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ST MARY S HOSPITAL   (Japan)

Author keywords

Cancer vaccine; Cytotoxic T lymphocyte; Immunotherapy; Renal cell carcinoma; SART1 antigen

Indexed keywords

HLA A ANTIGEN; SART1 ANTIGEN; TUMOR REJECTION ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR REJECTION;

EID: 0033917409     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002400000103     Document Type: Article

References (32)

1. Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, Itoh K (1990) Patterns of human tumor-infiltratine lymphocytes in 120 human cancers. Arch Surg 125: 200
2. Belldegrun A. Muul LM, Rosenberg SA (1988) Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 48: 206
3. Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethé B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178: 489
4. deKernion JB, Ramming KP, Smith RB (1978) The natural history of metastatic renal cell carcinoma: a computer analysis. J Urol 120: 148
5. De Baker O, Arden KC, Boretti M, Vantomme V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P, Van den Eynde B, Boon T, van der Bruggen P (1999) Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res 59: 3157
6. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autoloaous cytolytic T lymphocytes. J Exp Med 179: 921
7. Gaugler B, Brouwenstijn N, Vantommc V, Szikora JP, Van der Spek CW, Patard JJ, Boon T, Schrier P, Van den Eynde BJ (1996) A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 44: 323
8. Goedegebuure PS, Douville LM, Li H, Richmond GC, Schoof DD, Scavone M, Eberlein TJ (1995) Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukm-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J Clin Oncol 13: 1939
9. Hayakawa K, Morita T, Augustus LB, von Eschenbach AC, Itoh K (1992) Human renal-cell carcinoma cells are able to activate natural killer cells. Int J Cancer 51: 290
10. Imanishi T, Akazawa T, Kimura A, Tokunaga K, Gojobori T (1992) Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T (eds) HLA 1991, vol 1. Oxford Scientific Publications. Oxford, pp 1065-1220
11. International Union Against Cancer (UICC) (1992) TNM atlas. 3rd edn, 2nd revision. Springer, Berlin Heidelberg New York
12. Iwamoto O, Nagao Y, Shichijo S, Eura M, Kameyama T, Itoh K (1997) Detection of MAGE-4 protein in sera of patients with head-and-neck squamous-cell carcinoma. Int J Cancer 70: 287
13. Karp SE (1998) Low-dose intravenous interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma. J Immunother 21: 56
14. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T Cells infiltratinsi into tumor. Proc Natl Acad Sci USA 91: 3515
15. Kawamoto M, Shichijo S, Imai Y, Imaizumi T, Koga T, Yanaga H, Itoh K (1999) Expression of the SART-1 tumor rejection antigen in breast cancer. Int J Cancer 80: 64
16. Kikuchi M, Nakao M, Inoue Y, Matsunaga K, Shichijo S, Yamana H, Itoh K (1999) Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes. Int J Cancer 81: 459
17. Kim TY, von Eschenbach AC. Filaccio MLD, Hayakawa K, Parkinson DR, Balch CM, Itoh K (1990) Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma. Cancer Res 50: 5263
18. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon JL, Laurent C, Naeyaert JM, Plagne R, Deraemaeker R, Knuth A, Jäger E, Brasseur F, Herman J, Coulie PG, Boon T (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63: 883
19. Matsumoto H, Shichijo S, Kawano K, NishidaT, Sakamoto M, Itoh K (1998) Expression of the SART-1 antigens in uterine cancers. Jpn J Cancer Res 89: 1292
20. Morgan DJ, Kreuwel HTC, Fleck S, Levitsky HI, Pardoll DM, Sherman LA (1998) Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J Immunol 160: 643
21. Nakao M, Yamana H, Imai Y, Toh Y, Toh U, Kimura A, Yanoma S, Kakegawa T, Itoh K (1995) HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res 55: 4248
22. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med 4: 328
23. Robbins PF, El-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg SA (1995) Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 154: 5944
24. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, White DE, Steinberg SM (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85: 622
25. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME. Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med 4: 321
26. Shichijo S. Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K (1998) A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 187: 277
27. Sugita S, Sagawa K, Mochizuki M, Shichijo S, Itoh K (1996) Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. Int Immunol 8: 799
28. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K (1995) Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 55: 3478
29. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182: 689
30. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643
31. Wong FS, Karttunen J, Dumont C, Wen L, Visintin I, Pilip IM, Shastri N, Pamer EG, Janeway Jr CA (1999) Identification of an MHC class I - restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nature Med 5: 1026
32. Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K (1999) Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 59: 4056